Review of the preclinical work NKR-2 published in Future Oncology
Download the free guide
Boost your gains
Effectiveness in vitro on different cancer models
In vivo evidence of efficacy in a model of pancreatic cancer human
Mont-Saint-Guibert, Belgium Celyad (Euronext Brussels and Paris, and NASDAQ : CYAD), the biopharmaceutical company, belgian leader in the development of cellular therapies, AS-T, today announced the publication in the journal with reading committee, “Future Oncology” journal summarizing the preclinical work performed on NKR-2, the cell therapy product, BECAUSE-T is currently tested in the framework of the clinical trial THINK.
The review entitled “Exploiting Natural Killer Group 2D Receptors for CAR-T cell therapy” also provides new results confirming the effectiveness in vitro of cells CAR-T NKR-2 against different human cancer cell lines, original leukemic, colorectal, and pancreatic.
Finally, Celyad publishes new data demonstrating the ability of cells CAR-T NKR-2 to effectively respond has of established tumors of pancreatic cancer in human xenograft models in immunodeficient mice.
These preclinical studies have been carried out with Professor Charles Sentman, long-time collaborator of Celyad, and again confirm the selection of the guidance course of study in the framework of the test THINK.
Dr David Gilham senior Vice President of Research & Development department : “This publication provides important new preclinical evidence to support the field of cancer indications studied in the test THINK. This is an example of the work that we are to continue to define and understand the mechanisms of action of cells CAR-T NKR-2 in order to identify new elements to support our clinical development program “.
Dr Christian Homsy, CEO of Celyad : “We are delighted to provide further preclinical evidence that validate our approach in a clinical trial THINK, through which we aim to demonstrate the potential of the cells BECAUSE T-NKR-2 as an innovative technology in the treatment of cancer “.
The journal of Celyad can be found on the website of Future Oncology: http://www.futuremedicine.com/doi/abs/10.2217/fon-2017-0102
About Celyad
Celyad is a company’s clinical-stage biopharmaceutical in the development of cellular therapies, BECAUSE-T. The company uses its expertise in cellular development to target the cancer. The platform NKR-T Celyad is based on T-Cell changes in order to push them to express a Receptor of Natural Killer Cells (NK). This technology offers a potential therapeutic very wide, both in solid tumors than in the blood. BECAUSE-T NKR-2 is the product most advanced candidate of Celyad in oncology. This therapy has been the subject of a first clinical study of Phase I study to evaluate the safety of the product in patients with two types of blood cancer, Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM), This study was successfully completed in September 2016. Celyad was founded in 2007. The company is based in Mont-Saint-Guibert, Belgium, and Boston, in the United States. The actions of Celyad are listed on Euronext Brussels and Euronext Paris under the symbol CYAD. The ADSS are quoted on the NASDAQ Global Select Market under the symbol ” CYAD “.
For more information on Celyad, go on www.celyad.com
About the study THINK
THINK (THerapeutic Immunotherapy with NKR-2) is a Phase I, multicenter, international (Europe/Usa) in multiple-dose, study to evaluate the safety and clinical activity of cells CAR-T NKR-2 autologous, The study covers seven indications of which five solid tumors (colorectal, ovarian, breast, and pancreas), and two tumors hematological (myeloid leukemia and multiple myeloma). The study will focus on three levels of doses will be adjusted according to the weight of the patient and which will start to 3×108 to then reach 1×109 and finally 3×109 cells CAR-T NKR-2 injected. At each dose level, patients receive three successive injections of cells CAR-T NKR-2 and this, two weeks apart, The party increasing dose of the study will focus on 24 patients, while the expansion phase of the study will enroll 86 patients additional.
About the platform cell NKR-T Celyad
Celyad is developing a platform cell CAR-T single, using a Receptor of Natural Killer Cells (NK) transduces on lymphocytes T. The target platform for a wide range of solid and hematologic tumors. Unlike the approaches, BECAUSE-T conventional, which only target one type of tumor antigen, the receptors of natural killer cells (NK) allow a single receptor to recognize multiple tumor antigens. The principal product candidate of Celyad, BECAUSE-T NKR-2, is a T lymphocyte, BECAUSE that one was modified so that it expresses a receptor for human NK cells : the activating receptor NKG2D. BECAUSE-T NKR-2, triggers the destruction of cancer cells when it binds to one of the eight types of ligands it is known that they are upregulated by more than 80 % of the tumors.
The preclinical results indicate that AS-T NKR-2 mechanisms of action, multiple that go beyond the direct destruction of cancer cells. BECAUSE-T NKR-2 inhibits the mechanisms that allow tumors to evade the immune system, activates and recruits immune cells, anti-tumor and blocking the blood supply to the tumor. These mechanisms induce an adaptive immune response, that is to say, the development of immunological memory specific and durable against the antigens of the tumor-targeted.
In contrast to therapeutic approaches BECAUSE T-traditional, and on the basis of preclinical studies, the program AS-T NKR-2 current Celyad does not use any preparatory treatment, which decreases the lymphocytes, which avoids the toxicities associated with chemotherapy and preserves the integrity of the immune system.
Celyad works with both the development of an approach for autologous and allogeneic CAR-T NKR-2. In the framework of the approach, BECAUSE-T NKR-2 autologous, Celyad takes the own T lymphocytes of the patient and the program to express NKG2D in order to efficiently target cancer cells. In the approach to allogeneic Celyad, in T cells from healthy donors are programmed to also express inhibitory molecules of T cell receptors (TCR Inhibitory Molecules – TIM), so that the reprogrammed cells of the donor are not rejected by healthy tissue of the patient (disease of the graft against the host).
Preclinical research underlying this technology was initially conducted at Dartmouth College by Dr. Charles Sentman, and has been the subject of numerous publications in scientific journals.
Download the free guide
Boost your gains
